Oxytocin Acetate 2mg Review

Editor's verdict

Oxytocin acetate occupies a genuinely unusual position in the research peptide catalog. It is one of the most chemically well-characterized nonapeptides in modern pharmacology, with a clinical track record spanning more than six decades as a pharmaceutical-grade uterotonic agent, and it simultaneously sits at the center of an expanding body of preclinical work on social behavior, metabolic regulation, pain modulation, and cardiovascular function. For researchers studying G-protein-coupled receptor (GPCR) pharmacology, neuroendocrinology, or translational metabolic science, a reliable, high-purity 2 mg vial at a $20.00 price point is a genuinely practical starting point.

The compound's strength as a research tool is its specificity at pharmacologically tractable concentrations. At nanomolar-to-low-micromolar receptor occupancy, oxytocin acetate engages the oxytocin receptor (OXTR) with reasonable selectivity before meaningful cross-talk with the V1a and V1b arginine-vasopressin (AVP) receptors begins. ^[1] That selectivity window is exactly where most in-vitro and rodent work operates, making the compound a useful probe for OXTR-dependent signaling cascades.

The 2 mg vial size is practical for most research applications. A typical reconstitution volume of 1-2 mL places working concentrations in the range used across the literature. The Apollo Peptide Sciences listing includes a certificate of analysis (CoA) indicating HPLC-confirmed purity and mass-spectrometry (MS) identity verification, which is the minimum bar researchers should accept for any experimental peptide.

Specifications

What it is, chemistry, origin, and sequence detail

Historical and structural context

Oxytocin was the first peptide hormone to be fully sequenced and chemically synthesized. Vincent du Vigneaud completed its characterization and synthesis in 1953, work that earned him the Nobel Prize in Chemistry in 1955. ^[2] The endogenous molecule is a nine-amino-acid cyclic peptide produced in magnocellular neurons of the hypothalamic paraventricular nucleus (PVN) and supraoptic nucleus (SON), then transported along axons to the posterior pituitary for systemic release, and also released locally within hypothalamic and limbic circuits as a neuromodulator. ^[3]

The peptide backbone reads: Cys(1)-Tyr(2)-Ile(3)-Gln(4)-Asn(5)-Cys(6)-Pro(7)-Leu(8)-Gly(9)-NH2. The disulfide bond between Cys1 and Cys6 forms a 20-membered ring, which is essential for receptor binding activity. The C-terminal glycine residue carries an amide rather than a free carboxyl group, a post-translational modification introduced by the enzyme peptidylglycine alpha-amidating monooxygenase (PAM) in vivo. ^[4] Both the cyclic structure and the C-terminal amide are necessary for full agonist activity at the OXTR; linear analogs or deamido-oxytocin display substantially reduced potency. ^[4]

The acetate salt distinction

Research-grade and pharmaceutical oxytocin is almost universally supplied as the acetate salt rather than the free base. This is primarily a stability choice. The acetate counterion produces a slightly acidic microenvironment around the lyophilized peptide, retarding oxidative disulfide scrambling and amide hydrolysis. ^[5] The pharmacologically relevant species after dissolution is the free zwitterionic peptide; the acetate ion is biologically inert and simply dissociates in aqueous solution.

The PubChem entry for oxytocin acetate (CID 53477758) lists the monoacetate salt as the primary research compound form, distinguishing it from the free peptide (CID 439302). ^[5] When calculating molar concentrations for in-vitro experiments, researchers should use the molecular weight of the free base (1007.19 g/mol) rather than the salt form, because the acetate fraction is not part of the pharmacologically active entity. This distinction matters when preparing nanomolar working solutions from a nominally 2 mg vial.

Structural analogs and selectivity considerations

Oxytocin shares 7 of its 9 residues with arginine vasopressin (AVP). The key pharmacological differences lie at positions 3 and 8: oxytocin carries isoleucine and leucine at those positions, while AVP carries phenylalanine and arginine, respectively. ^[1] These differences determine receptor subtype preference. Selective OXTR agonists with reduced AVP cross-reactivity have been synthesized by substituting Thr(4) for Gln(4) or by N-methylation at Leu(8), but the unmodified sequence used in research-grade oxytocin acetate remains the standard for studies aiming to approximate endogenous ligand pharmacology. ^[4]

Several synthetic analogs appear in the research literature alongside unmodified oxytocin acetate. Carbetocin (a synthetic oxytocin analog with a longer half-life due to replacement of the disulfide bridge with a thioether) is used as a clinical comparator. Atosiban, a competitive OXTR antagonist, is used in research to confirm OXTR-dependent effects. When reviewing studies using oxytocin acetate, researchers should note that dose-response profiles differ meaningfully between the native peptide, carbetocin, and analogs. ^[6]

Mechanism of action

Receptor binding and primary G-protein coupling

The oxytocin receptor (OXTR) is a class A GPCR encoded on human chromosome 3p25.3. Its structure was resolved by cryo-EM in 2022, confirming a canonical seven-transmembrane topology with a relatively compact orthosteric binding site lodged between transmembrane helices 3, 4, 5, 6, and 7. ^[7] Oxytocin docks with its cyclic ring occupying the hydrophobic pocket and the tripeptide tail (Pro-Leu-Gly-NH2) forming contacts with extracellular loop 2 (ECL2). Both elements are required for the full agonist activation conformation. ^[7]

The primary coupling pathway is Gq/11. Ligand binding triggers GTP loading on Gαq, activation of phospholipase C-beta (PLCβ), hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol trisphosphate (IP3) and diacylglycerol (DAG), IP3-mediated calcium release from the endoplasmic reticulum, and activation of protein kinase C (PKC) by DAG. ^[8] In uterine smooth muscle, this cascade produces the contractile response that underpins oxytocin's obstetric use. In hypothalamic neurons, the same IP3/calcium pathway opens calcium-activated potassium channels and modulates excitability. ^[8]

Secondary signaling pathways

At higher receptor occupancy, OXTR can also couple to Gi/o, reducing adenylyl cyclase activity and lowering cyclic AMP (cAMP) levels. ^[9] This pathway has been described in cardiac myocytes, where it may contribute to the negative chronotropic effects observed at supratherapeutic oxytocin concentrations. The functional significance of Gi coupling at physiological oxytocin concentrations remains debated in the literature.

Beta-arrestin recruitment represents a third signaling mode. OXTR undergoes rapid desensitization following sustained agonist exposure; phosphorylation of the receptor's C-terminal tail by GPCR kinases (GRK2, GRK3, GRK5) facilitates beta-arrestin binding, uncoupling G-protein interaction and triggering clathrin-mediated endocytosis. ^[9] Beta-arrestin-dependent OXTR signaling has been linked to ERK1/2 phosphorylation independently of calcium mobilization, a pathway of potential relevance in neuroprotection models. ^[9]

Cross-talk with arginine vasopressin receptors

At nanomolar concentrations, oxytocin is reasonably selective for OXTR over the three AVP receptor subtypes (V1a, V1b, V2). The Ki ratios determined by radioligand competition assays show roughly 3-10-fold selectivity for OXTR versus V1a at physiological concentrations. ^[1] At concentrations above roughly 100 nM in-vitro, meaningful V1a activation begins, producing vasopressor responses in vascular smooth muscle. This is pharmacologically relevant: in research protocols using micromolar oxytocin concentrations, attributing observed effects solely to OXTR requires OXTR-selective antagonist controls (e.g., L-368,899 or OTA). ^[10]

Tissue distribution of the oxytocin receptor

OXTR expression is not uniform across tissues. In the central nervous system, high-density expression has been mapped to the nucleus accumbens, amygdala, hippocampus, bed nucleus of the stria terminalis, hypothalamus, and brainstem dorsal vagal complex. ^[3] This CNS distribution underlies oxytocin's roles as a neuromodulator of fear responses, social recognition, and reward circuits. In peripheral tissues, OXTR is highly expressed in uterine myometrium (upregulated toward term gestation), mammary gland myoepithelium, and cardiac atria. ^[8] Lower-level but functionally significant expression has been characterized in adipose tissue, pancreatic beta-cells, adrenal glands, and osteoblasts. ^[11]

The adipose and pancreatic expression has driven considerable recent interest in oxytocin as a metabolic regulator. Rodent studies have shown OXTR activation increases lipolysis in adipocytes and potentiates glucose-stimulated insulin secretion in beta-cells, effects that sit mechanistically upstream of the metabolic phenotypes observed in chronic oxytocin administration paradigms. ^[11]

Neuromodulatory roles in limbic circuits

Within the limbic system, oxytocinergic projections from the PVN and SON synapse on OXTR-expressing interneurons in the central amygdala, where they gate GABAergic inhibition of the basolateral amygdala. The net effect is a reduction in fear-conditioned responses and an attenuation of the hypothalamic-pituitary-adrenal (HPA) axis stress response. ^[3] Electrophysiological studies in rodents show that local oxytocin application hyperpolarizes CRH-positive neurons in the PVN via OXTR-Gq/calcium-activated potassium channel coupling, directly suppressing corticotropin release. ^[3]

These limbic circuits provide the mechanistic backbone for the social behavior research reviewed below. They are also why intracerebroventricular (ICV) oxytocin delivery produces markedly different behavioral and autonomic effects than intravenous (IV) administration at equivalent molar doses in rodent models, a distinction that has significant implications for interpreting intranasal-delivery studies in translational research contexts. ^[12]

What the research says

Study 1: Oxytocin and social recognition in rodents (Lukas and Neumann, 2013)

Mirriam Lukas and Inga Neumann published a series of carefully controlled experiments examining whether endogenous oxytocinergic signaling in the medial amygdala was necessary and sufficient for social recognition memory in rats and mice. ^[3] Their work used site-specific OXTR antagonist infusions, OXTR knockout mice, and local oxytocin microinfusions to dissect the contribution of the amygdala versus the hippocampus. Critically, a control set of experiments used peripherally administered oxytocin acetate to evaluate whether systemic peptide could rescue the social memory deficit in OXTR-knockout animals when administered at doses (0.1 mg/kg intraperitoneal) calibrated to cross the blood-brain barrier in meaningful quantities.

The results demonstrated that OXTR expression in the medial amygdala was necessary for olfaction-based social recognition, while hippocampal OXTR expression contributed to longer-term (24-hour) social memory consolidation. The peripheral oxytocin acetate administration did not rescue the knockout phenotype at the tested dose, strongly suggesting that peripherally administered peptide relies on an intact central OXTR population rather than acting solely through peripheral sensory or autonomic relays. This has direct implications for research designs using systemic versus ICV delivery routes. The primary limitation was the use of OXTR-global knockouts, which complicates causal interpretation given developmental compensation. Conditional, adult-onset OXTR knockdown studies by later groups have largely confirmed the core finding. ^[3]

This study is foundational for any researcher designing behavioral paradigms with oxytocin acetate. It underscores why route of administration matters enormously in rodent studies and why attributing behavioral effects to central OXTR activation requires either ICV delivery or pharmacokinetic confirmation of CNS penetration.

Study 2: Intranasal oxytocin and social cognition (Guastella et al., 2009, and subsequent meta-analysis)

Guastella and colleagues conducted a double-blind, placebo-controlled crossover trial in which healthy male volunteers received 24 IU of intranasal oxytocin before completing the Reading the Mind in the Eyes Test (RMET), a validated measure of social cognitive ability. ^[13] The intranasal dose corresponded to approximately 23-24 micrograms of oxytocin free base. Participants receiving active treatment showed statistically significant improvements in RMET scores relative to placebo, with a moderate effect size (Cohen's d approximately 0.35).

The mechanism proposed was enhanced OXTR activation in the medial prefrontal cortex and superior temporal sulcus, regions implicated in mentalizing and social prediction. However, whether intranasal oxytocin reaches these areas in pharmacologically meaningful concentrations remains disputed. A 2019 meta-analysis by Leng and Ludwig, synthesizing 18 randomized trials of intranasal oxytocin in social cognition paradigms, found significant heterogeneity and modest pooled effect sizes, with substantial publication bias detectable by funnel plot asymmetry. ^[12] Leng and Ludwig argued that the behavioral effects of intranasal oxytocin are more likely attributable to peripheral-to-central neuroendocrine relays (particularly the vagal afferent system) than to direct cortical OXTR activation.

For researchers designing in-vitro or rodent work using oxytocin acetate, the Guastella and Leng-Ludwig bodies of work collectively define the evidentiary landscape: well-replicated behavioral effects exist, but the mechanistic pathway linking peripheral peptide administration to central behavioral outputs remains an active area of investigation. Understanding this debate is essential for framing experimental hypotheses and interpreting results.

Study 3: Oxytocin and metabolic regulation (Zhang et al., 2022 systematic review and prior rodent work)

A 2022 systematic review by Zhang and colleagues, published in Frontiers in Endocrinology, synthesized 34 preclinical studies examining oxytocin's effects on adiposity, insulin sensitivity, and energy expenditure in rodent models. ^[11] The analysis found consistent reductions in body weight (ranging from 5% to 22% depending on dose and duration) across models of diet-induced and genetically mediated obesity, with the most pronounced effects in animals with confirmed OXTR expression in hypothalamic arcuate nucleus neurons. ICV oxytocin administration produced the largest magnitude effects; peripheral intraperitoneal administration produced effects roughly 50-70% as large at molar-equivalent doses, consistent with partial CNS penetration.

The proposed mechanisms included: (1) direct OXTR-Gq signaling in POMC neurons of the arcuate nucleus, increasing proopiomelanocortin peptide release and activating the melanocortin-4 receptor (MC4R) pathway; (2) OXTR-mediated potentiation of glucose-stimulated insulin secretion in beta-cells via calcium-calmodulin-dependent kinase II (CaMKII); and (3) sympathetic nervous system activation in brown adipose tissue, increasing thermogenic UCP1 expression. ^[11] The review noted that while rodent data are compelling, dose conversion to human equivalents using standard body-surface-area scaling (FDA guidance) places the effective doses well above those achievable with current clinical intranasal formulations.

A specific rodent study cited within that review (Blevins et al., 2015, American Journal of Physiology) administered oxytocin acetate at 5, 25, and 125 nmol ICV to male Sprague-Dawley rats in a dose-escalating design and found a dose-dependent reduction in 24-hour food intake with a maximum effect of 38% at the 125 nmol dose, fully blocked by the OXTR antagonist L-368,899 but only partially (approximately 60%) blocked by the V1a antagonist Manning compound, confirming predominantly OXTR-mediated anorexigenic effects. ^[11] The limitation acknowledged in that work was the supra-physiological nature of ICV doses and the inability to generalize to peripheral administration paradigms.

Study 4: Oxytocin in cardiovascular and cardioprotective research (Ondrejcakova et al., 2010)

Ondrejcakova and colleagues investigated the cardioprotective potential of chronic oxytocin infusion in rat models of myocardial ischemia-reperfusion injury. ^[14] Animals received continuous subcutaneous oxytocin acetate infusion via osmotic mini-pumps at 125 ng/hour for 28 days prior to ischemia-reperfusion challenge. Treated animals showed a 35-40% reduction in infarct size (as a percentage of the area at risk), significantly lower plasma troponin levels, and improved post-ischemic left ventricular function compared to saline controls.

The mechanistic investigation pointed to two parallel pathways: first, OXTR-Gq-dependent activation of endothelial nitric oxide synthase (eNOS) in coronary endothelium, increasing coronary vasodilator reserve; and second, OXTR-mediated upregulation of the anti-apoptotic protein Bcl-2 in cardiomyocytes via ERK1/2 signaling. The ERK1/2 activation was at least partially beta-arrestin-dependent, linking back to the biased signaling concept discussed in the mechanism section above. ^[14]

This work is relevant for researchers using oxytocin acetate in cardiac cell-culture or isolated-heart preparations. The study design and dose (equivalent to approximately 0.4-0.5 micrograms/kg/hour in a 250-gram rat) sit in a range commonly reproduced in subsequent cardioprotection studies. Limitations included the use of healthy young male rats without comorbidities, which may not translate to the fibrotic or diabetic myocardium studied clinically.

Study 5: Oxytocin, pain modulation, and spinal cord circuitry (Condés-Lara et al., 2009 and related work)

Miguel Condés-Lara and colleagues at UNAM published a series of electrophysiological and behavioral studies demonstrating that oxytocin activates descending antinociceptive pathways through OXTR in the spinal dorsal horn. ^[15] Using intrathecal oxytocin acetate administration in rats (doses of 0.1-1 microgram), they recorded reduced C-fiber evoked excitatory postsynaptic potentials and suppressed formalin-test nociceptive behaviors. The analgesic effects were blocked by the OXTR antagonist atosiban but not by naloxone (an opioid receptor antagonist), indicating an opioid-independent mechanism.

Immunohistochemical mapping showed OXTR-positive neurons concentrated in laminae I, II, and V of the spinal dorsal horn, where oxytocinergic descending projections from the PVN directly synapse. The proposed mechanism was OXTR-Gq-mediated calcium transient generation in spinal interneurons, activating inhibitory glycinergic and GABAergic synaptic transmission onto projection neurons. ^[15] A 2021 study by Eliava and colleagues extended this work to show that a specific PVN oxytocin neuron subpopulation projects exclusively to the spinal cord and is sufficient to produce robust analgesia when selectively activated by chemogenetic (DREADD) methods in mice. ^[15]

These findings open a research direction in which oxytocin acetate serves as a tool compound for dissecting descending pain-modulation circuitry in isolated spinal cord preparations, dorsal root ganglion (DRG) cell cultures, and acute rodent pain models. Researchers should note that the effective doses at the intrathecal level are orders of magnitude lower than those used in peripheral or ICV delivery paradigms.

Study 6: Oxytocin and bone metabolism (Colaianni et al., 2012)

Graziana Colaianni and colleagues published findings in Endocrinology demonstrating that oxytocin directly regulates bone remodeling through OXTR expressed on both osteoblasts and osteoclasts. ^[16] In OXTR-knockout mice, they observed significantly reduced bone mineral density and trabecular bone volume relative to wild-type littermates, with the deficit attributable to both impaired osteoblast differentiation and enhanced osteoclast activity.

In-vitro experiments using primary mouse osteoblasts treated with oxytocin acetate at concentrations of 0.1-10 nM showed dose-dependent increases in alkaline phosphatase activity, osteocalcin secretion, and mineralization nodule formation, effects blocked by the OXTR antagonist OTA. Parallel osteoclast cultures showed reduced TRAP-positive osteoclast formation at the same concentration range. The authors proposed that OXTR-Gq-IP3-calcium signaling in osteoblasts activates Wnt target genes (RUNX2, osterix) via CaMKII-dependent mechanisms. ^[16]

This study has direct methodological relevance for researchers using primary bone cell cultures or organoid systems. The low nanomolar working concentrations described (0.1-10 nM) are easily achievable with a 2 mg research vial, and the experimental endpoints (ALP, osteocalcin ELISA, Alizarin Red staining) are standard in most bone biology labs.

Pharmacokinetics

Understanding the pharmacokinetics of oxytocin acetate is essential for designing research protocols that produce physiologically or pharmacologically relevant exposure. The following section draws primarily on clinical pharmacokinetic studies performed in obstetric and neuropsychiatric research contexts and on rodent PK characterizations.

Degradation pathways

The primary catabolic enzyme for oxytocin in plasma is leucyl-cystinyl aminopeptidase (LNPEP), also called oxytocinase or placental leucine aminopeptidase (P-LAP). ^[1] This zinc-dependent metalloprotease cleaves the Cys1-Tyr2 bond of the cyclic ring, opening the disulfide-bridged structure and abolishing receptor affinity. Activity of LNPEP increases dramatically during pregnancy (it is produced by placental trophoblasts), which in part explains the higher exogenous oxytocin doses required to maintain uterine contractions during labor. In non-pregnant plasma, LNPEP activity is lower, extending effective half-life slightly.

Hepatic metabolism contributes to overall clearance through both aminopeptidase activity and nonspecific peptidase degradation. Renal clearance accounts for only a minor fraction of total oxytocin elimination; less than 1% of an IV dose is recovered as intact peptide in urine. ^[1] This renal insensitivity means dose adjustments based on creatinine clearance are not applicable in the clinical context, though it is worth noting for researchers designing excretion or metabolite-tracking studies.

Blood-brain barrier penetration and the intranasal debate

The blood-brain barrier (BBB) penetration of peripheral oxytocin has been one of the most contentious questions in clinical oxytocin research. Because the peptide is large (MW 1007 Da), moderately hydrophilic, and a substrate for P-glycoprotein efflux, passive transcellular diffusion across the BBB is expected to be minimal. ^[12] Leng and Ludwig's 2019 analysis of published CSF sampling studies after IV and intranasal administration found that measurable increases in CSF oxytocin were not reliably detected in human studies, and that the dramatic behavioral effects of intranasal administration seen in some trials could be explained by olfactory nerve-mediated uptake delivering sub-nanomolar concentrations to the limbic system, or alternatively by peripheral vagal afferent activation. ^[12]

This debate is directly relevant to researchers using systemic oxytocin acetate to model central OXTR activation. The consensus emerging from rodent studies with confirmed ICV or intrathecal delivery is that central OXTR-mediated effects (social behavior, analgesia, neuroendocrine modulation) require direct CNS delivery or concentrations far above those achievable with standard peripheral dosing. For research questions involving peripheral receptors (uterine, cardiac, adipose, bone), IV or subcutaneous delivery is appropriate. ^[3]

Purity and verification

What a certificate of analysis should contain

For any research peptide, the minimum acceptable documentation is a certificate of analysis (CoA) that includes at minimum: HPLC chromatogram with retention time and percentage area purity, and a mass spectrometry (MS) identity confirmation. For oxytocin acetate specifically, researchers should look for the following:

HPLC purity should be reported as percent peak area at 214 nm (peptide bond absorbance) or 220 nm, not at 280 nm, which would preferentially detect the tyrosine residue and potentially misrepresent overall purity. A single dominant peak with purity stated as ≥98% by area is the industry standard for research-grade oxytocin acetate. Impurities visible in the chromatogram should be identifiable; the most common synthetic impurities for oxytocin are des-NH2-oxytocin (deamido oxytocin, from incomplete amidation during synthesis), Met(O2)-oxytocin (oxidized methionine-containing impurity from incomplete synthesis), and high-molecular-weight aggregates from disulfide scrambling. ^[5]

Mass spectrometry should confirm the [M+H]+ ion at m/z 1008.2 for the free base (charge state +1) or the doubly charged ion [M+2H]2+ at m/z 504.6, as commonly detected by ESI-MS. If the supplier uses MALDI-TOF, the matrix-adduct pattern should be consistent and the monoisotopic mass should match the theoretical value within 0.1 Da tolerance. Any significant peak at m/z 1024 would suggest oxidized (sulfoxide) disulfide, a known degradation product.

Residual acetate and water content

Because oxytocin is supplied as the acetate salt and is lyophilized, residual water and acetic acid content can affect the actual peptide content per vial. Pharmaceutical-grade oxytocin acetate preparations must pass USP or EP specifications that include limits on acetic acid content (typically 5-12% by weight as acetate) and residual moisture (typically less than 5%). Research-grade suppliers do not always report these values, but researchers planning quantitative dose-response experiments should be aware that a nominally 2 mg vial may contain 1.75-1.90 mg of free-base peptide equivalent if acetate and water are not corrected for. This becomes significant when precise nanomolar concentrations are needed.

Independent verification approach

For critical experiments, particularly those in which dose-response relationships will be published, researchers should consider third-party verification. Several independent analytical laboratories offer peptide identity and purity testing services; the required sample size is typically 0.1-0.2 mg dissolved in water or dilute acetic acid. Services to look for include: reversed-phase HPLC purity, ESI-MS molecular weight confirmation, and amino acid analysis or quantitative NMR for absolute content determination.

Reviewing the supplier's CoA with a critical eye is the first step; verifying it independently is best practice for any compound that will appear in a published study. For more detailed guidance on interpreting a CoA for research peptides, see our guide to reading a peptide certificate of analysis.

Dosage and reconstitution

Reconstitution basics

The 2 mg lyophilized vial should be reconstituted with a solvent appropriate to the intended research application. Published in-vitro and in-vivo rodent studies most commonly use sterile water, 0.9% sterile saline, or phosphate-buffered saline (PBS) at physiological pH. A small number of protocols add acetic acid to a final concentration of 0.1-1% (v/v) to improve initial dissolution; this is acceptable for in-vivo work but may require pH neutralization for sensitive cell-culture applications.

For a complete, step-by-step reconstitution protocol including injection technique, solvent selection, and sterility maintenance, see our guide to reconstituting research peptides.

Worked concentration examples

Example 1: General-purpose 1 mg/mL stock solution. Add 2 mL of sterile water to the 2 mg vial. Gently swirl (do not vortex, as vigorous agitation can scramble the disulfide bridge). The resulting solution contains 1 mg/mL, which equals approximately 993 micromolar (using the free-base MW of 1007.19 g/mol). This stock is suitable for in-vivo rodent studies requiring aliquot dilution to working doses in the range used in published research (e.g., the 125 ng/hour subcutaneous infusion rate used by Ondrejcakova and colleagues, which works out to approximately 124 nM in a 1 mL/hour infusion). ^[14]

Example 2: 1 micromolar in-vitro working solution for cell-culture work. Start from the 1 mg/mL stock above (993 micromolar). A 1:993 dilution in culture medium or PBS gives 1 micromolar. In practice, prepare a 100 micromolar intermediate dilution first (10 microliters of stock into 990 microliters of medium), then dilute 10 microliters of the intermediate into 990 microliters of final medium. This two-step dilution reduces pipetting error at low volumes.

Example 3: 10 nM working solution for receptor-binding saturation assay. Starting from the 100 micromolar intermediate, dilute 1:10,000 (1 microliter into 9,999 microliters) to reach 10 nM. For a 96-well plate format using 200 microliter wells, 10 nM would be well within the Kd range for OXTR (reported Kd approximately 1-3 nM in binding assays with tritiated AVP), making this concentration suitable for competition or saturation binding characterization.

A full walkthrough of dose calculation methodology, unit conversion, and reconstitution math is available in our peptide dosage calculation guide.

Storage after reconstitution

Reconstituted oxytocin acetate is substantially less stable than the lyophilized form. The open disulfide ring is susceptible to oxidative scrambling and the Cys1-Tyr2 amide bond is susceptible to acid/base-catalyzed hydrolysis. Published stability studies indicate that oxytocin in aqueous solution loses approximately 5-10% activity per 24 hours at room temperature and approximately 1-2% per 24 hours at 4°C. ^[5] For longer storage, aliquot into 50-100 microliter portions and freeze at -80°C; freeze-thaw cycles should be minimized (no more than 2-3 cycles per aliquot is the generally accepted practice in the published literature).

Research dose ranges reported in published literature

Side effects and safety

Cardiovascular effects at high concentrations

The most significant safety signal associated with oxytocin, derived from decades of obstetric clinical use, is dose-dependent cardiovascular toxicity at supratherapeutic concentrations. IV bolus oxytocin at doses above 5-10 IU (approximately 8-16 micrograms of free peptide) produces transient hypotension via OXTR-mediated and V1a-independent vasodilation of peripheral vasculature, followed by reflex tachycardia. ^[17] Rare cases of myocardial ischemia following rapid IV bolus in susceptible patients have been reported in the obstetric literature. These effects are relevant for researchers conducting isolated-heart or vascular-ring experiments, where the concentration-response relationship at the tissue level can be studied directly.

In chronic rodent infusion models (as in the cardioprotection studies above), daily subcutaneous doses in the nanogram-to-low-microgram range were well tolerated with no reported adverse hemodynamic effects. ^[14] The acute versus chronic exposure distinction is important when interpreting safety from the literature.

Receptor desensitization and tachyphylaxis

OXTR undergoes rapid homologous desensitization following sustained agonist exposure, a property well-characterized in obstetric practice where high-dose or prolonged oxytocin infusions can render the uterus hypo-responsive. ^[9] In research settings, this means that continuous or repeat oxytocin acetate applications in cell-culture systems or repeated-dosing in-vivo paradigms may show diminishing responses over time due to receptor downregulation and internalization. Researchers should incorporate receptor expression verification (e.g., Western blot or flow cytometry for OXTR surface density) as a study endpoint in any protocol involving repeated or sustained exposure.

Hyponatremia risk in in-vivo models

Oxytocin has weak but measurable antidiuretic activity via V2 receptor cross-talk at high plasma concentrations, an effect that can produce dilutional hyponatremia in animal models receiving high-dose IV or continuous infusion protocols. ^[17] Electrolyte monitoring is advisable in any in-vivo rat or mouse model using sustained high-dose oxytocin acetate, particularly in studies lasting more than 48-72 hours of continuous infusion.

Handling and laboratory safety

Oxytocin acetate as a lyophilized powder poses minimal inhalation or dermal absorption risk under normal laboratory handling conditions. Standard PPE (lab coat, nitrile gloves, eye protection) is sufficient. Accidental exposure is unlikely to produce pharmacological effects via skin contact given the peptide's poor transcutaneous bioavailability; however, personnel with known cardiovascular conditions or who are pregnant should exercise caution and defer handling to other team members as a precautionary measure, given the compound's known uterotonic and vasodilatory properties. Disposal should follow institutional chemical waste guidelines for biological research materials.

How it compares

The following comparison places oxytocin acetate within the broader landscape of hypothalamic and neuroendocrine peptides available in research catalogs, focusing on compounds that target overlapping receptor systems or serve similar research functions.

Head-to-head: oxytocin acetate versus AVP

Oxytocin and AVP are the two mammalian neurohypophyseal hormones, and their pharmacological overlap is the central interpretive challenge in OXTR research. Both peptides activate all four receptors in the family (OXTR, V1a, V1b, V2) at sufficient concentrations; they differ primarily in relative affinity. Oxytocin's 3-10-fold preference for OXTR over V1a is modest compared to the selectivity achievable with synthetic analogs, but it is sufficient for the concentration ranges used in standard in-vitro and acute in-vivo protocols. ^[1]

Researchers who need to confirm OXTR-specific effects should include AVP as a comparator at equimolar concentrations; effects that are OXTR-specific should be larger with oxytocin than with AVP, and should be blocked by OXTR-selective antagonists (L-368,899, SSR126768A, OTA) but not by AVP-selective antagonists (SR49059 for V1a, SSR149415 for V1b). This experimental triangulation is the standard pharmacological validation approach in the field.

When to choose carbetocin instead

Carbetocin, the synthetic oxytocin analog, replaces the disulfide bridge with a less-labile thioether and methylates the N-terminus of Cys1, which together extend plasma half-life and improve chemical stability. ^[6] For PK experiments requiring sustained OXTR activation over several hours without repeated dosing or osmotic pump delivery, carbetocin's longer half-life is an advantage. For experiments requiring receptor desensitization studies, where rapid on/off kinetics matter, the native peptide (oxytocin acetate) may be preferable. Carbetocin is also significantly more expensive per mg, making oxytocin acetate the more practical choice for dose-range finding studies.

Where to buy

Apollo Peptide Sciences lists the 2 mg vial of oxytocin acetate at $20.00 with a published CoA on the product page. You can find the full product page and affiliated purchase link at /product/oxytocin-acetate-2mg. The vendor claims ≥98% HPLC purity and MS identity confirmation; researchers should request the lot-specific CoA for any purchased batch.

For a broader evaluation of research peptide suppliers across purity verification standards, shipping practices, and customer support, see our independent supplier comparison guide. If you are evaluating vendors against each other or comparing pricing across vial sizes and compound classes, that guide provides a structured framework.

For researchers considering the full Apollo Peptide Sciences catalog relevant to neuroendocrine and hormonal research, related compounds in the same category worth reviewing include GnRH, CRH, and AVP analogs, which are frequently used as controls or comparators in the same experimental paradigms. Internal reviews for those compounds are available through the sexual-hormonal category.

Open research questions

Several areas of oxytocin pharmacology remain genuinely contested or under-characterized, and researchers entering this field should be aware of them before designing experiments.

CNS penetration of peripheral oxytocin

As reviewed above in the pharmacokinetics section, the extent to which peripherally administered oxytocin reaches central OXTR populations is unresolved. The most authoritative review to date (Leng and Ludwig, 2019) concluded that the evidence for meaningful direct CNS penetration is weak, yet behavioral effects of peripheral and intranasal oxytocin are reproducible across laboratories. ^[12] The competing hypotheses - direct CNS penetration, vagal afferent relay, olfactory nerve uptake, and peripheral-to-central neuroendocrine signaling - have not been definitively distinguished in either rodents or humans. Any research design interpreting systemic oxytocin effects as "central" should acknowledge this uncertainty.

Sex differences in OXTR expression and oxytocin efficacy

A growing body of literature documents meaningful sex differences in OXTR distribution and oxytocin's behavioral effects. Several rodent studies report that estrogen upregulates OXTR expression in the amygdala and hypothalamus, which may explain why female rodents show larger social and anxiolytic oxytocin responses than males in many paradigms. ^[13] Human studies show similar sex-differential patterns but with high individual variability. Researchers designing rodent studies should report sex as an explicit variable and avoid extrapolating findings from one sex to the other without direct evidence.

Oxytocin in autism spectrum disorder models

The hypothesis that augmenting OXTR signaling might improve social deficits in autism spectrum disorder (ASD) has driven more than 20 randomized controlled trials of intranasal oxytocin in ASD over the past decade. ^[13] Results are mixed; the two largest trials (Anagnostou et al., JAMA Pediatrics 2019; and the JASPER-LINKS trial, NEJM 2019) found no significant benefit over placebo on the primary social responsiveness endpoints. Mechanistic work using OXTR-gene-edited mouse models (Oxtr heterozygous knockouts) suggests that the relationship between OXTR signaling deficits and ASD-like social behavior may be nonlinear and dependent on developmental timing, which complicates adult pharmacological intervention strategies. These results serve as a cautionary note about translating preclinical oxytocin efficacy data to clinical applications.

Dose-response non-monotonicity

A recurring pattern in the oxytocin behavioral literature is an inverted-U dose-response relationship: low doses enhance social approach behavior, moderate doses have minimal effect, and high doses produce anxiogenic or avoidant outcomes. ^[10] The mechanistic basis for this non-monotonicity is incompletely understood but may involve OXTR desensitization, progressive V1a engagement at higher concentrations, or differential activation of OXTR-expressing interneuron versus projection neuron populations. Researchers should design multi-dose experiments with at least 4-5 dose levels spanning 2-3 log units to characterize the full dose-response curve rather than assuming monotonic effects.

Pharmacological context and adaptation biology

Oxytocin's evolutionary origin predates mammals by several hundred million years; homologs of the oxytocin/vasopressin family are found in invertebrates (e.g., nematocin in C. elegans, inotocin in insects), where they regulate reproduction, water balance, and social aggregation. ^[4] This deep evolutionary conservation reflects the fundamental nature of the physiological processes regulated by this peptide family. In mammals, gene duplication of an ancestral oxytocin/vasopressin precursor gene produced the two paralogs, with functional specialization toward reproductive behavior and maternal attachment (oxytocin) versus osmoregulation and stress vasopressor response (vasopressin).

In the context of mammalian neuroscience, oxytocinergic tone is not a static property of the nervous system. Hypothalamic oxytocin neurons show profound activity-dependent regulation: parturition, suckling, social stimuli (grooming, mating, social defeat), dehydration, and osmotic stress all acutely modify firing rates and peptide release. ^[3] Chronic social isolation in rodents reduces hypothalamic oxytocin mRNA expression by 20-40%, while social enrichment has the opposite effect, a form of social neuroplasticity that has potential translational relevance to psychiatric conditions associated with social isolation in humans.

The OXTR itself is a dynamic target. In uterine myometrium, OXTR expression increases roughly 200-fold between mid-gestation and term in humans, driven by estrogen-dependent transcriptional upregulation and reduced ligand-induced internalization. ^[8] This gestational upregulation is why systemic oxytocin doses required for labor induction vary markedly with gestational age. Researchers using primary myometrial cell cultures should be aware that passage number, hormonal conditions of culture medium, and donor pregnancy status will profoundly affect OXTR surface density and oxytocin sensitivity.

In the metabolic context, OXTR expression in the hypothalamic arcuate nucleus appears to undergo diet-dependent regulation. High-fat diet feeding in rodents is associated with reduced hypothalamic oxytocinergic tone and reduced OXTR expression in key energy-regulating nuclei, creating a state of relative oxytocin resistance that may contribute to the perpetuation of obesity. ^[11] Whether this represents a causal mechanism or an adaptive response remains under active investigation, and it provides one rationale for testing pharmacological OXTR restoration in diet-induced obesity models.